NEVVI Medicare utilization intelligence
+ Build a code basket
Market snapshot

Nationwide CY2024

Medicare Part B FFS · CY2024 · as published by CMS
J9022 Injection, atezolizumab, 10 mg HCPCS · Chemotherapy treatment
Classification Treatment Chemotherapy Chemotherapeutic Agent (CMS RBCS)
First observed 2018
National scale 92,688 services ▼ 52.6% YoY · 229 beneficiaries (CY2024, Medicare FFS)
Medicare paid $6.2M · $66.43 avg / service, national
CMS descriptor · RBCS classification · Medicare Part B physician/supplier claims, 12-year window
Billing groups
6
Named-group FFS services
79,440
FFS of Medicare
49%
Services YoY
-52.6%
FFS enrollment -2.2%
Estimated all-Medicare volume FFS + estimated MA estimate
~139,309 services

79,440 observed fee-for-service (57%) · ~59,869 estimated Medicare Advantage. Scaled from the observed floor by each state’s fee-for-service share (FFS share as of 2024) — scaled estimate — assumes MA utilization mirrors FFS; not an observation. How we scale

Top states — J9022 (CY2024)

Disclosed Medicare fee-for-service services by billing state; open a bar for that state's ranked market.

Named-group submitted charges
$22.3M
Named-group allowed amount
$6.6M
Named-group Medicare payments
$5.3M
Avg charge / svc
$281
Avg allowed / svc
$84
Avg payment / svc
$67
Average charge per group
$169 6 groups · avg submitted charge / service $466
Market analyticsPlatform
a taste of the twelve-year trend layer

Or just look at it: nuclear heart imaging (78452) in Arizona is open as a live example — the full paid view, real data.

View the live example →

Nevvi's market analytics platform — code baskets, market structure and share, the twelve-year trend layer — is built and not launched yet. We're gathering interest in it.

Notify me at launch →
Refine: practice size any 5+ 25+ 100+ independent only
Filter results:

Email me this CSV

Data year: CY2024 CY2023 CY2022 locked column CY2021 locked column CY2020 locked column
Physician groups ranked by J9022 services, highest first, CY2024
# Physician group activate to sort City activate to sort St activate to sort Specialty activate to sort Providers activate to sort J9022 svcs sorted descending — activate to reverse Submitted charges activate to sort Avg charge activate to sort Medicare $ locked column Share* activate to sort Phone
1 JACKSON ONCOLOGY ASSOCIATES JACKSON MS HEMATOLOGY/ONCOLOGY 11 21,120 $9,841,920 $466 premium 100.0% (601) 974-5600
2 CANCER CENTER OF KANSAS PA WICHITA KS HEMATOLOGY/ONCOLOGY 27 20,616 $4,974,408 $241 premium 82.0% (316) 262-4467
3 CENTRAL ARKANSAS RADIATION THERAPY INSTITUTE INC LITTLE ROCK AR HEMATOLOGY/ONCOLOGY 90 16,656 $3,139,008 $188 premium 100.0%
4 ONCOLOGY-HEMATOLOGY ASSOCIATES OF CENTRAL ILLINOIS P C PEORIA IL NURSE PRACTITIONER 62 9,000 $1,885,440 $209 premium 100.0% (309) 243-3000
5 LEXINGTON HEALTH INC WEST COLUMBIA SC NURSE PRACTITIONER 909 5,640 $953,160 $169 premium 100.0% (803) 744-4900
6 CANCER CENTER OF KANSAS PA WICHITA MN HEMATOLOGY/ONCOLOGY 27 4,464 $1,081,032 $242 premium 100.0% (316) 262-4467
7 TEXAS ONCOLOGY PA DALLAS TX PHYSICIAN ASSISTANT 995 1,944 $436,248 $224 premium 100.0%

*Share of the state's disclosed Medicare-FFS services for the primary code, counted once per clinician. "St" is the state the volume was billed from: a group appears in each state where its clinicians bill Medicare, with that state's volume and share ("City" is the group's registered location). Group figures sum clinicians affiliated with exactly one group; clinicians in several groups are listed in each group's drill-down but not volume-attributed to any single group, so shares reflect attributable volume. See Methods.

Comparing against an all-payer estimate?

These are exact counts from Medicare fee-for-service claims — roughly a third to half of most procedure markets, depending on payer mix. Modeled all-payer databases project the remainder statistically; we publish the audited floor and label it as such. Same market, different denominator. How the numbers reconcile →